AOMs will likely have a smaller impact on general population morbidity
Mar 2025: Gerresheimer completed a series of fill finish capacity investments at its Bnde, Germany site, adding polymer syringe processing lines targeting ophthalmic and biologic applications requiring silicone free environments
Agree to release and hold harmless the Company from any damages, claims, liability, losses, expenses or actions related to the product's shelf life arising from the usage
Pull back on training and see what happens
A 2023 review of GLP-1 receptor agonist use in post-bariatric surgery populations found that patients with anatomical changes to their digestive tract benefited from individualized dosing protocols rather than standard titration schedules
This warning stems from animal studies showing thyroid tumors in rodents, though it remains unknown whether Zepbound causes these tumors in humans